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New mouse model for polycystic kidney disease with both recessive and
dominant gene effects. In the course of studying the genetics of chioram-
bucil mutagenesis, we have uncovered a new model for autosomal
polycystic kidney disease (PKD). In the homozygous condition, the gene,
jcpk, causes a very severe disease characterized by cysts in all segments of
the nephron. Death usually occurs before 10 days of age. Extrarenal
involvement was also noted; enlarged bile ducts, pancreatic ducts, and gall
bladder often accompanied the PKD. In addition, approximately 25% of
the aged +/jcpk heterozygotes show evidence of glomerulocystic dis-
ease. This gene maps to Chromosome 10 between two DNA markers,
DlOMit20 and DlOMit42. Because this gene causes extrarenal abnormal-
ities and because it has a heterozygote effect, it may be an informative
animal model for the commonly occurring human adult dominant PKD.
Polycystic kidney disease (PKD) is a class of commonly occur-
ring hereditary diseases, affecting one in every 200 to 1000 in-
dividuals and accounting for 8 to 10% of all end stage renal
diseases [1—3]. The adult dominant form of PKD (ADPKD) is the
most common and is usually detected by renal dysfunction
occurring in early adulthood although it has also been found in
infants and aborted fetuses [1]. ADPKD is also associated with
liver cysts (33% of patients), bile duct enlargements (50% of
patients), pancreatic duct proliferation (10% of patients), and
occasionally cerebral aneurysms (6% of patients) [1]. The etiology
of ADPKD is unknown. Recently one of the genes that causes
ADPKD, called PKD1, has been cloned [4]. Abnormalities in this
gene account for 85% of ADPKD with the remainder of cases
most likely due to abnormalities at a second gene, called PKD2
[5—7]. So far the partial gene sequence of the PKD1 gene has not
revealed the causative nature of this disease.
Autosomal recessive PKD (ARPKD) is a rarer disorder occur-
ring in one in every 6000 to 14,000 individuals [1, 2]. The disease
affects both the kidney and liver and usually results in death
shortly after birth. Hepatic lesions generally consist of abnormal-
ities in the number and dilation of the bile ducts and in fibrosis of
the portal connective tissue. At least one of the gene(s) determin-
ing ARPKD has been identified and maps to human Chromosome
6 [8].
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One way of learning more about the causes of this disease is to
study mouse models that imitate the human situation. Several
mouse models for PKD have been described. No dominant form
of the disease has yet been characterized in the mouse; however,
several autosomal recessive ones exist. These include cpk, located
on Chromosome 12 [9, 10], pcy, located on Chromosome 9 [11,
12],jck; which is non-allelic to either cpk orpcy [13] and bpk, also
distinct from cpk, pcy, and jck [14].
Finally, Moyer et al [15] have recently reported another case of
genetically derived PKD. This disease is the direct result of
insertional mutagenesis with a transgene. This gene, called Tg737,
maps to Chromosome 14 and has been cloned and sequenced [15].
Recently, we have uncovered yet another new model for
autosomal polycystic disease. In the homozygous condition, this
disease appears to be the most severe of all of the known
mutations. A late onset polycystic disease is also present in a
quarter of the heterozygotes. The mutation causing this disease
was induced in our mutagenesis studies involving the drug,
chlorambucil [16]. Here, we describe the characteristics of this
disease and its genetics. The gene determining this disease has




Mice were either bred at the Wadsworth Center, obtained from
The Jackson Laboratory, or obtained from Oak Ridge National
Laboratories. The Tester strain is commonly used in mutagenesis
experiments at the Oak Ridge National Laboratories; it contains
7 recessive morphological or coat color mutations (a, b, c, d, s, se,
p) [17].
Chiorambucil mutagenesis
The mutagenesis scheme and recovery of this mutant have been
previously described [16]. Briefly, male (101 X C3H)F2 mice were
treated with chlorambucil at a dose of 10 mg/kg. They were then
mated with Tester females. The progeny were then intercrossed
twice so that recessive visible mutations could be recovered [16].
The PKD phenotype was recognized by a grossly enlarged abdo-
men appearing in 3 to 10 day old mice.
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Histological studies
At various times after birth, litters from +Ijcpk )< +Ijcpk
matings were examined for the presence of PKD. Mice exhibiting
gross symptoms of PKD were sacrificed. Kidneys and other organs
were fixed in either Bouin's or phosphate buffered formalin.
Paraffin sections were made and then stained with hematoxylin
and eosin or Periodic-Acid-Schiff stain.
Simple sequence length polymorphisms (SSLPs)
The polymerase chain reaction (PCR) was used to detect
SSLPs. DNA was prepared from tails according to a modified
version of the procedure described by Laird et al [18]. Primers for
the SSLPs have been published [19, 20] and PCR conditions are
according to Dietrich et al [19]. Magnesium concentrations and
annealing temperatures were optimized for each primer pair.
SSLPs were analyzed by electrophoresis of radiolabeled PCR
products on denaturing acrylamide gels as described by Dietrich
et al [19] or by use of nonradiolabeled material and a silver
staining kit available from Biorad [21].
Results
Gross anatomy
Homozygousjcpk/jcpk mice were detected as early as three days
after birth by a protruding abdomen. Runting often accompanied
the kidney disease. No jcpkljcpk homozygote survived longer than
20 days, even on an outbred background. Generally, the animals
died between 7 and 10 days after birth. Death was most likely a
result of either renal failure or impaired breathing due to pressure
on the diaphragm from the kidneys. When autopsied, mice had
grossly enlarged kidneys filled with fluid cysts (Fig. 1). Approxi-
mately 50% of the mice also showed visible gall bladder enlarge-
ment. An example of such an enlarged gall bladder is seen in the
autopsied mouse pictured in Figure 1. No other abnormalities
were noted.
Histology
Examination of histological sections showed that the jcpkljcpk
kidneys were highly abnormal (Fig. 2 A-C). Even as early as birth,
cysts were evident. These cysts continued to increase in size and
number until the death of the mouse. No unusual tubular
morphology was noted other than the dilation of the tubules and
ducts. There was no apparent difference between males and
females in the rate of renal enlargement. At birth, most of the
cysts appeared in nephrons contained within the inner cortical and
medullary regions. In general these cysts were smaller than those
seen later at four and seven days (Fig. 2). By four days, most areas
of the kidney contained cysts including the outer cortex. Over the
next few days of development, these cysts continued to enlarge
until the entire renal architecture became distorted and cyst-filled.
At seven days, the cysts were so extensive that, aside from a few
small but rare islands of unaffected structures, no normal glomer-
uli, tubules or ducts could be seen in the majority of the kidney.
Extrarenal involvement was also apparent in these mice. On
histological examination of the liver and pancreatic ducts, extreme
dilations of both the bile ducts and pancreatic ducts were noted Fig. 1. Gross anatomy of nonnal and polycystic animals at 7 days of age. A,
(Figs. 3 and 4). In general some degree of hepatic or pancreatic normal animal; B,polycystic animal; C, polycystic animal with kidneys andliver removed to expose the full size of the gallbladder. Abbreviations are:duct involvement was evident in all of the mice exhibiting G, gallbladder; K, kidney. (Original magnification 2.8x.)polycystic kidneys. In most mice, the degree of renal dtsease
correlated with the degree of extrarenal abnormalities.
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signs of glomerulocystic disease. Numerous glomerular cysts were
noted in both kidneys (Fig. 5A). One kidney also showed a greatly
dilated pelvis consistent with hydronephrosis. An exophytic pelvic
neoplasm with features of a malignant epithelial lesion was also
found in this kidney and probably accounted for the urinaty tract
obstruction with resulting hydronephrosis. No cysts were noted in
the proximal or distal tubules. Three other heterozygotes, aged 10
to 15 months, also showed areas containing glomerular cysts,
examples of which are shown in Figure 5 B and C. It was common
for these cysts to appear in small clusters or foci. When the liver
of one of these heterozygotes was examined, it also contained
tortuous and dilated bile ducts similar to the ones found in young
jcpkljcpk homozygotes. In addition, another aged heterozygote
(22 months old) exhibited two large fluid filled hepatic cysts (over
5 mm in diameter) (Fig. 4D). These cysts were filled with a clear
fluid and showed no connection to the bile system. Thus, out of
the 17 aged heteozygotes examined, four showed some cystic
abnormalities in the kidney glomeruli and one showed cysts in the
liver. A comparable number of age- and strain-matched normal
controls were also autopsied. None of these mice exhibited similar
lesions. Because of the frequency of the glomerular cysts in these
aged heterozygotes, it is very likely that this condition is a direct
consequence of the jcpk gene.
Genetics
We used multiple SSLP (simple sequence length polymor-
phism) DNA markers to localize the jcpk gene to Chromosome
10. For these studies, intercrosses of +Ijcpk X +Ijcpk were used.
Homozygous jcpk/jcpk mice were detected by a protruding abdo-
men. Phenotypes were confirmed by examination of the kidneys.
Approximately 19% of the mice (109 of 565) from these inter-
crosses were diagnosed as polycystic. This figure is slightly below
the expected 25% for the inheritance of a recessive phenotype;
however, it was also noted that these intercrosses yielded a high
percentage of deaths between days 0 and 15. Thus, it is probable
that some of the polycystic mice died before their disease became
visually apparent.
All homozygotes were typed for a series of SSLP markers. Once
it was established that jcpk was located on Chromosome 10, only
Chromosome 10 markers were used for further analysis. Results
of these studies placed jcpk between DlOMit2O and DlOMit42,
approximately 3 cM distal to DlOMit2O and 5 cM proximal to
DiOMit 42 (Tabfe 1). Currently, more extensive genetic studies
are underway to find polymorphic markers that are closer to jcpk
Discussion
Mouse models for human kidney diseases have been extremely
useful for analyzing the etiology and treatment of PKD. For
example, mouse models have confirmed the view that cysts are
derived from the renal tubules. Moreover, animal models have
provided useful tools for investigating the effects of drugs and
hormones on cyst progression. Finally, because of the similarities
between the mouse and human genomes, identifying the mouse
Fig. 2. Normal and polycystic kidneys at 0, 4, and 7 days of age. A, B, and genes that cause PKD can lead to the rapid identification of
C are of polycystic kidneys at 0, 4, and 7 days, respectively. All photos are similar genes in humans. The polycystic disease described in this
at the same magnification. (Original magnification 6.25X.) report promises to be no exception. This mouse model can be
used both for the fine genetic mapping of factors influencing the
Seventeen aged heterozygotes were also examined for signs of development of the abnormal cysts as well as a suitable experi-
cystic disease. These ranged in age from 10 months to 22 months. mental animal model to determine the physiological and biochem-
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Fig. 3. Pancreas and pancreatic ducts from polycystic and normal animals at 7 days of age. D indicates ducts. A. Normal pancreas with normal sized
pancreatic duct. B. jcpk pancreas and grossly enlarged duct. Magnification of B is 1/2 that of A so that the duct could be seen completely. (Original
magnifications of A 25X and B 12.5X.)
and heterozygote effects, it may have some advantages over other most severe of any of the previously described mouse PKD
models, mutations. It affects multiple tubule segments as well as Bowman's
The jcpk mutation produces a unique phenotype that has many capsule. On either a C57BL/6 or an outbred genetic background,
of the characteristics of the human autosomal recessive and animals become severely polycystic by 7days of age, usually die by
dominant forms of the disease. First, it is very early acting and the 10 days and never survive longer than 20 days. Prior to the
p
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Fig. 4. Liver and bile ducts from polycystic animals at 4 days of age. A and B. Livers from 4 day old jcpk/jcpk homozygotes showingexpanded and tortuous
bile ducts surrounding portal vessels. V indicates portal vein. Bile ducts are the smaller ducts that line the portal veins. C is an enlargement of B. D.
Liver cyst from aged heterozygote. Multiple smaller cysts were also observed in areas around large cysts. (Original magnifications: A and B, 25 X; C,
bOX; D, lOX.)
recovery of this mutation, the cpk gene caused the earliest acting
polycystic disease. Homozygous cpklcpk mice become symptom-
atic between 10 and 13 days and die between 20 and 30 days of
age, although on the DBAJ2J background the effects of cpk
become more severe [22]. These two genes do not interact since
testcrosses between +/cpk and +Ijcpk mice indicate that com-
pound cpk/jcpk heterozygotes are normal in all respects.
A rat model for autosomal dominant PKD also has severe
effects in the homozygous state [23]. Homozygous Cy/Cy rats
develop massively enlarged kidneys and die at approximately
three weeks of age. Like jcpk/jcpk homozygotes, these homozy-
gous mutant rats exhibited cystic dilation in all nephron segments
where little renal architecture remains at the time of death.
Heterozygote Cy/+ rats also show a late onset disease but this
disease was not restricted to the glomeruli like in +Ijcpk heterozy-
gotes.
Like some other mouse models of PKID, the jcpk mutation
shows extrarenal involvement. Both hepatic and pancreatic ducts
are affected. Bile ducts in the portal areas of the liver appear
especially tortuous similar to the picture seen in human autosomal
recessive PKD [fl. Liver abnormalities have also been noted in at
least three other mouse PKDs. In +Icpk heterozygotes, focal
dilations of the biliary tree can be seen [24, 25].These increase in
severity in mice over a year in age. Moreover, when the cpk gene
was transferred to the DBA/2J background, gross pancreatic
abnormalities and, to a lesser extent, bile duct abnormalities, were
often noted in cpklcpk homozygotes [22]. In another mouse
model, the bpklbpk mouse, extrarenal involvement was very
common where dilatations and hyperplasia of the entire intrahe-
patic and extrahepatic biliaiy tract generally accompanied the
development of the polycystic kidney disease. Finally, the new
insertional PKD mutation described by Moyer et al [151 also
causes pronounced abnormalities in the intrahepatic biliary tract.
In contrast, two other mouse mutations, pcy and jck, show no
hepatic or pancreatic involvement.
One of the more unique features of the jcpk mutation is its
effect on the size of the gallbladder. Approximately 50% of the
jcpkljcpk mice exhibited some enlargement of the gallbladder with
the degree of enlargement varying from a small increase in size to
a gross enlargement such as that seen in Figure 1. This gallbladder
enlargement has not been reported as a consistent feature in any
of the human forms of PKD [1] or in any of the mouse models so
far examined.
Thus, the jcpk mutation seems to cause a unique set of
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DlOMit44 30 11 36.6 8.8
Dl0Mit20 99 3 3.0 1.7
Dl0Mit42 105 5 4.8 2.1
DlOMitl0 84 8 9.5 3.2
Only jcp k/jcpk homozygotes were included in these analyses. These data
represent the accumulation of meioses from several different crosses. In
some of these crosses, individual markers were not informative, that is,
one or both of the parents were homozygous for a given allele. Recom-
bination frequencies were calculated according to Green [34] and given in
terms of frequency standard error. Chromosome 10 markers are listed
in their order from the centromere [19, 20].
Fig. 5. Histo1o of kidneys from aged heterozygotes. A. +/jcpk kidney
exhibiting multiple glomerular cysts. B and C. +/jepk kidneys from 2
heterozygotes showing small foci of glomerular cysts. (Original magnifi-
cation of A, B, and C is 25x.)
abnormalities. This unique phenotype suggests that the jcpk gene
is affecting a different pathway than other PKDmouse genes. Its
similarity to human forms of PKD remains to be resolved.
However, one must keep in mind that often the same abnormal
gene product in the mouse will cause a different set of abnormal-
ities in humans.
The abnormalities noted in the aged heterozygotes may also
make this model an interesting one for study. The abnormalities
found in these mice are reminiscent of glomerulocystic disease in
humans [2]. Cysts in this disease are confined to Bowman's
capsule. Interestingly, there is a common association of this
disease with ADPKD [2]. Since our preliminary results suggest
that older mice develop these types of cysts, the animal model may
be useful in studying the environmental events that stimulate
glomerulocyst formation. In our model, these cysts are most often
localized in small foci such as the one seen in Figure 3B. The
significance of these foci is not known; however, it is suggestive
that they may be the result of some triggering from a localized
environmental stimulus.
One of several current theories regarding the etiology of PKD
is that it is a proliferative disease where uncontrolled cell multi-
plication leads to enlarged tubules and glomeruli [reviewed in 1,
26]. This theory is supported by several transgenic mouse models
where inserted oncogenes, under the control of promoters that
are active in the renal tubular epithelium, cause a dominant
polycystic kidney disease [24, 27—32]. Moreover, Moyer et al [15]
have found that the PKD candidate gene associated with Tg737
possesses tetratricopeptide repeats that are characteristic of cer-
tain cell cycle control genes, implying that this PKD aswell may be
associated with abnormal proliferation. In our model, if a prolif-
erative abnormality exists, it must occur early in the homozygote
but much later in the heterozygote. Moreover, it must involve
some activity that is common to several kinds of ductal tissue
including that found in the kidney, bile ducts, pancreatic ducts,
and gallbladder. The rare occurrence of a neoplasm in one of our
aged heterozygotes is also consistent with this theory. Alterna-
tively, etiologies due to abnormal ion transport and/or abnormal
basement membranes have also been proposed to explain PKD
[reviewed 1, 3, 26]. Current information on the jcpk genetic model
cannot rule out any of these possibilities.
This new jcpk mutation gives us the opportunity to locate and
clone a causative PKD gene. Because of its genetic origin and
chromosomal location, tools for its cloning are readily available.
First, there are several genetic markers in close proximity to the
estimated location of jcpk. Currently, we are outcrossing this
mutation to Mus musculus castaneous so that we can take advan-
tage of all of the polymorphic variation at these loci. Analysis of
the F2 intercross offspring should allow us to map a gene within
0.5 cM of jcpk. Since this mutation was induced by the chemical
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mutagen, chiorambucil, and all known chiorambucil mutations are
deletions or chromosomal rearrangements [33], it is vety likely
that our mutant represents a deletion mutation as well. Thus, we
will hopefully identify the causative gene by its absence, partial
absence or rearrangement in the mutant organism. Once identi-
fied, efforts will be directed toward the elucidation of its involve-
ment in both normal renal development as well as the various
pathological states of PKD.
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